|

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

RECRUITINGPhase 4Sponsored by Pfizer
Actively Recruiting
PhasePhase 4
SponsorPfizer
Started2023-10-03
Est. completion2032-02-22
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations14 sites
View on ClinicalTrials.gov →

NCT06057402

Summary

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Participants must agree to follow the reproductive criteria as outlined in the protocol
* Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).

Exclusion Criteria:

* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
* Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.

Conditions2

CancerMultiple Myeloma

Locations14 sites

UCHealth Poudre Valley Hospital
Fort Collins, Colorado, 80524
UCHealth Harmony
Fort Collins, Colorado, 80528
UCHealth Greeley Hospital
Greeley, Colorado, 80634
Longs Peak Hospital
Longmont, Colorado, 80504
UCHealth Longs Peak Medical Center
Longmont, Colorado, 80504

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.